<doc xmlns:ss="urn:schemas-microsoft-com:office:spreadsheet"><general><doctitle>Chapitre 3 : Méthodes d'évaluation médico-économique</doctitle><docauthor>Georges WEIL</docauthor></general><pages><page><pagetitle>@Chapitre 3  :  Méthodes d'évaluation  médico-économique@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide0.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>1</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Sommaire@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide1.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>2</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Généralités@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide2.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>3</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Définition (HAS)  @</pagetitle><pageaudio></pageaudio><pagedisplay>Slide3.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>4</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Pourquoi la nécessité d'arbitrages collectifs@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide4.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>5</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Il faut faire des choix portant sur le cadre d'évaluation@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide5.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>6</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Toujours des comparaisons@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide6.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>7</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Typologie de l'évaluation@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide7.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>8</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Qui évalue ?@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide8.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>9</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Qu'est ce qu'on évalue@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide9.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>10</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Quand évaluer ?@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide10.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>11</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Les différents types d'études@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide11.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>12</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Etudes coût-efficacité@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide12.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>13</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Les études coûts-efficacité@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide13.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>14</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Indications et limites@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide14.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>15</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@En avoir pour son argent@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide15.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>16</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Exemple : organisation du dépistage du cancer du col utérin et introduction de la vaccination contre les HPV@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide16.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>17</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@ Données économiques (vaccination et dépistage pour le cancer du col de l'utérus)@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide17.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>18</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Résultats@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide18.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>19</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@L'Exemple des Unités Neuro-Vasculaires (UNV)@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide19.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>20</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Etudes coût - utilité@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide20.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>21</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Étude coût-utilité@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide21.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>22</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Les QALY's@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide22.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>23</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Les QALYS@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide23.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>24</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Indications des ECU@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide24.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>25</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@ Exemple : traitements anti-cancéreux@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide25.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>26</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Exemples d'interventions comparées@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide26.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>27</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Limites et critiques@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide27.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>28</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Etudes coût - bénéfices@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide28.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>29</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Étude coût-bénéfice@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide29.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>30</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Traitement de l'insuffisance rénale chronique terminale (en 2001)@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide30.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>31</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Exemple théorique (1)@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide31.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>32</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Exemple théorique (2)@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide32.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>33</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Exemple théorique (3)@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide33.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>34</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Exemple théorique (4)@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide34.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>35</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Les ECB, par rapport aux ECE, et ECU@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide35.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>36</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Les difficultés méthodologiques et éthiques@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide36.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>37</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Les outils de mesure@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide37.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>38</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Les normes@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide38.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>39</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@La dimension qualitative@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide39.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>40</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Attribuer une valeur monétaire aux résultats de santé@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide40.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>41</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Efficience, Efficience  !!!@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide41.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>42</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Conclusions@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide42.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>43</pagethumbnail><pagenotes></pagenotes></page><page><pagetitle>@Mentions légales@</pagetitle><pageaudio></pageaudio><pagedisplay>Slide43.swf</pagedisplay><pagevideo></pagevideo><pageduration>30</pageduration><pagethumbnail>44</pagethumbnail><pagenotes></pagenotes></page></pages></doc>